Company profile
Crescent Biopharma, Inc.
NASDAQ: CBIO · Healthcare · Biotechnology
#621 of 1,418 Healthcare companies by revenue
EA Score
65BFH 52DQ 69GM 95SS 62
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, Altman-Z · ↓ operating margin, net margin
Methodology →Revenue TTM
$11.9M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$153.9M
Employees
44
as of 2026-08-12
Market cap
$619.9M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$10.8M$10.8M2025
Net income-$153.9M-$153.9M2025
Operating income-$152.6M-$152.6M2025
Total assets$240.3M$240.3M2025
Liabilities$37.3M$37.3M2025
Equity$203.0M$203.0M2025
Revenue trend
FY2016 – FY2025 · USD
FY16
FY18
FY20
FY21
FY22
FY23
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Crescent Biopharma, Inc.’s revenue?
Crescent Biopharma, Inc. booked $10.8M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -1419.6% net margin.
Peers · Healthcare
GSRX Industries Inc.——Veri Medtech Holdings Inc.46DOntrak, Inc.——Christina Lake Cannabis Corp.65BVentura Cannabis & Wellness Corporation——PrimeMD Inc——Neighbors
Middlesex →Key facts
CEOJoshua T. Brumm
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: CBIO
Employees44
IPO date2014-01-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.